LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Biosensors Enable Rapid Multiplexed Pathogen Detection

By LabMedica International staff writers
Posted on 27 Jun 2013
An electronic chip has been created that can analyze blood and other clinical samples for infectious bacteria with record-breaking speed.

The advanced technology can identify the pathogen in a matter of minutes, and looks for many different bacteria and drug resistance markers in parallel, allowing rapid and specific identification of infectious agents.

Image: Platform for rapid molecular diagnostic testing (Photo courtesy of Xagenic Inc).
Image: Platform for rapid molecular diagnostic testing (Photo courtesy of Xagenic Inc).

Biomaterial engineers and other specialists at the University of Toronto (ON, Canada) developed an integrated circuit that could detect bacteria at concentrations found in patients presenting with a urinary tract infection. The solution circuit chip (SCC) consists of 100 working electrodes (WEs) with 30 off-chip contacts. It included 20 common WEs and 5 counter/reference (CE/RE) electrode pairs, with 25 probe wells to facilitate manual probe deposition and five separate liquid channels. One key to the advance was the design of an integrated circuit that could accommodate a panel of many biomarkers.

A set of peptide nucleic acid (PNA) probes were designed, synthesized and tested, and validated for sensitivity and specificity. It is these probes that make individual sensors specific for pathogens, as they are targeted to unique sequences within the genomes of the organisms. The probe set developed covered 90% of the common urinary tract pathogens and many of the major types of drug resistance that are encountered in a clinic. The results indicate that SCCs can be used for highly multiplexed pathogen detection, and can also be used to deliver the very rapid results needed to make diagnostic information clinically available.

Ihor Boszko, MSc, MBA, Director of Business Development at the molecular diagnostics company Xagenic (Toronto, ON, Canada) said the breakthrough could have significant practical implications. “This kind of highly sensitive, enzyme-free electrochemical detection technology will have tremendous utility for clinical diagnostics. Multiplexing of in vitro diagnostic approach adds the capability of simultaneously testing for multiple viruses or bacteria that produce similar clinical symptoms. It also allows for simple and cost effective manufacturing of highly multiplexed electrochemical detectors, which will certainly have a significant impact on the availability of effective diagnostic tools.” The study was published on June 12, 2013, in the journal Nature Communications.

Related Links:

University of Toronto
Xagenic



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS

Latest Microbiology News

New Test Diagnoses Bacterial Meningitis Quickly and Accurately
27 Jun 2013  |   Microbiology

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
27 Jun 2013  |   Microbiology

New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
27 Jun 2013  |   Microbiology